Orexigen looking for FDA approval in next few months, says Cowen Cowen noted Orexigen announced Q4 results last night and provided an update on its regulatory processes. The firm remains positive on Contrave's potential lifecycle management opportunities and reiterates its Outperform rating and $10 price target.
Orexigen weight loss drug recommended in Europe The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting a marketing authorization for Mysimba for weight management of overweight or obese adults. The medicine is recommended for use in addition to a reduced-calorie diet and physical activity. Mysimba is made by Orexigen.